Agenus

Based in Lexington, the United States, Agenus is a startup founded in 1994. Its most recent tracked round is IPO. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.

Agenus develops cancer immunotherapies, including a clinical pipeline of proprietary cancer vaccines and monoclonal antibodies that target the immune system for cancer therapy. The company has collaborations on checkpoint modulators with partners such as Merck and Incyte and is publicly listed on NASDAQ.